Literature DB >> 19554433

A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake.

Jun Li1, Fahima Nekka.   

Abstract

Fine individual drug intake data, generally collected by electronic monitoring devices, reveal that individual marked random patterns are likely to persist through long therapeutic periods. This work aims to establish the relationship between irregularity in drug intake and its potential impact on therapeutic outcomes, which will also serve as a basis for more objective interventions. First we proposed a direct way to extract the necessary information representing the patient drug intake history. To provide a fair evaluation of the pharmacological performance, we revisited several classical pharmacological indices and proposed new ones in the stochastic context of patient's drug intake irregularity. To illustrate our procedure, we have considered two cases of HIV treatment using a combination of lopinavir/ritonavir (Kaletra@) for once daily and twice daily regimens. We have quantified the impact on therapeutic effect of various characteristics in dosing histories, namely missing doses and deviations from nominal times. Using our newly defined pharmacological indices, we clearly showed the ability of our probabilistic approach in measuring the impact of noncompliance. As a direct fallout, we have discussed strategies to attenuate the impact of noncompliance through an optimal design of dosing regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19554433     DOI: 10.1007/s10928-009-9119-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  19 in total

1.  Adherence and drug resistance: predictions for therapy outcome.

Authors:  L M Wahl; M A Nowak
Journal:  Proc Biol Sci       Date:  2000-04-22       Impact factor: 5.349

2.  Pharmacodynamics of variable patient compliance: implications for pharmaceutical value.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-09-07       Impact factor: 15.470

3.  Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics.

Authors:  Laetitia Comté; Bernard Vrijens; Eric Tousset; Paul Gérard; John Urquhart
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-12       Impact factor: 2.745

4.  Assessing pharmacokinetic variability directly induced by drug intake behaviour through development of a feeding behaviour-pharmacokinetic model.

Authors:  J Li; C E Petit-Jetté; D Gohore Bi; F Fenneteau; J R E Del Castillo; F Nekka
Journal:  J Theor Biol       Date:  2007-12-03       Impact factor: 2.691

5.  Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.

Authors:  K M L Crommentuyn; B S Kappelhoff; J W Mulder; A T A Mairuhu; E C M van Gorp; P L Meenhorst; A D R Huitema; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

6.  Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.

Authors:  Bernard Vrijens; Eric Tousset; Richard Rode; Richard Bertz; Steve Mayer; John Urquhart
Journal:  J Clin Pharmacol       Date:  2005-04       Impact factor: 3.126

7.  Patient adherence to prescribed antimicrobial drug dosing regimens.

Authors:  Bernard Vrijens; John Urquhart
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

8.  Prediction of diltiazem plasma concentration curves from limited measurements using compliance data.

Authors:  A Rubio; C Cox; M Weintraub
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 9.  How can we predict bacterial eradication?

Authors:  Michael R Jacobs
Journal:  Int J Infect Dis       Date:  2003-03       Impact factor: 3.623

10.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

View more
  6 in total

1.  Variability and singularity arising from poor compliance in a pharmacokinetic model II: the multi-oral case.

Authors:  Lisandro J Fermín; Jacques Lévy-Véhel
Journal:  J Math Biol       Date:  2016-07-18       Impact factor: 2.259

2.  Compliance spectrum as a drug fingerprint of drug intake and drug disposition.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-19       Impact factor: 2.745

3.  A Bayesian approach for the estimation of patient compliance based on the last sampling information.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-29       Impact factor: 2.745

4.  Variability and singularity arising from poor compliance in a pharmacokinetic model I: the multi-IV case.

Authors:  Pierre-Emmanuel Lévy Véhel; Jacques Lévy Véhel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-30       Impact factor: 2.745

5.  Variability and singularity arising from a Piecewise-Deterministic Markov Process applied to model poor patient compliance in the multi-IV case.

Authors:  Lisandro J Fermín; Jacques Lévy-Véhel
Journal:  J Appl Stat       Date:  2020-01-07       Impact factor: 1.416

6.  What should patients do if they miss a dose of medication? A theoretical approach.

Authors:  Elijah D Counterman; Sean D Lawley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-10       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.